The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk categories in relation to the likelihood of breast cancer recurrence. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses adjuvant treatment decisions in early breast cancer patients with intermediate Oncotype DX RS results.
This content is supported by Genomic Health, Inc.
